Docetaxel as adjuvant therapy on patients with locally advanced breast cancer (LABC), after neoadjuvant chemotherapy with anthracyclines followed by radical surgery +/- radiotherapy

743 Background:The aim was to determine the benefit in Disease Free Survival (DFS) and Overall Survival (OS) of the docetaxel as adjuvant therapy LABC after multimodal therapy. Methods:761 patients with diagnosis of breast cancer were revised. 130 patients met criteria with stages II-B (T3N0M0), III-A, III-B, III-C that received treatment from Jan 1999 to March 2003. Combined modality consisted on a first phase with neoadjuvant chemotherapy (NCT) with anthracyclines, followed by Radical Mastectomy (RM) +/- Radiotherapy and Docetaxel for 4 cycles as adjuvant therapy. Results:51.5% had Stage III-A and 40% III-B,8.5% other (IIb, IIIC). 83.1% received 4 cycles of NCT (median of 4, range of 3 to 6). 127 patients (97.6%) received radiotherapy, 31 in preoperative manner and 96 postoperative. 95.4% underwent RM. Only 3.9% treated with conservative surgery. The median follow-up was 26.5 months (range 9–55 months). The DFS at 36 months was 60% (+/-7.8%) and the OS at 48 months was 71.52% (+/- 8.9%). The OS at 36 mo...